DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

Understanding Chronic Lymphocytic Leukemia

Recruiting

Conditions: Chronic Lymphocytic Leukemia

First Posted Date: 2019-07-22

Last Posted Date: 2024-10-22

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 2750

Registration Number: NCT04028531

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

INTREPId (INTermediate Risk Erection PreservatIon Trial)

Phase 2

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Drug: Bicalutamide
Drug: GnRH Agonist
Drug: Darolutamide
Radiation: Radiation Therapy

First Posted Date: 2019-07-18

Last Posted Date: 2024-11-19

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 234

Registration Number: NCT04025372

Locations: 🇺🇸
Stamford Hospital, Stamford, Connecticut, United States
🇺🇸
Beth Israel Deaconness Medical Center, Boston, Massachusetts, United States
🇺🇸
Brigham and Women Hospital, Boston, Massachusetts, United States

and more 8 locations

NeoVax With Nivolumab in Patients With Ovarian Cancer

Phase 1

Active, not recruiting

Conditions: Ovarian Cancer

Interventions: Drug: Nivolumab
Biological: NeoVax
Procedure: Core Needle Biopsy

First Posted Date: 2019-07-18

Last Posted Date: 2024-05-14

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 22

Registration Number: NCT04024878

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation

Phase 1

Conditions: Juvenile Myelomonocytic Leukemia
Myelodysplastic Syndromes
Acute Myeloid Leukemia
Myeloproliferative Neoplasm

Interventions: Biological: CIML NK
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2019-07-18

Last Posted Date: 2024-12-18

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 50

Registration Number: NCT04024761

Locations: 🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

18Fluorine-Fluciclovine PET/CT for Staging Muscle Invasive Bladder Cancer Preceding Radical Cystectomy

Early Phase 1

Active, not recruiting

Conditions: Urothelial Carcinoma
Bladder Cancer

Interventions: Drug: 18F-fluciclovine
Device: PET/CT

First Posted Date: 2019-07-12

Last Posted Date: 2024-01-23

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 16

Registration Number: NCT04018053

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma

Phase 2

Withdrawn

Conditions: Melanoma Stage III
Melanoma Stage IV

Interventions: Drug: Nivolumab
Drug: BMS-986205
Drug: Ipilimumab

First Posted Date: 2019-07-05

Last Posted Date: 2020-02-05

Lead Sponsor: Dana-Farber Cancer Institute

Registration Number: NCT04007588

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

A Trial of All-trans Retinoic Acid (ATRA) in Advanced Adenoid Cystic Carcinoma

Phase 2

Completed

Conditions: Adenoid Cystic Carcinoma

Interventions: Drug: Tretinoin

First Posted Date: 2019-06-27

Last Posted Date: 2023-01-23

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 18

Registration Number: NCT03999684

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

The Value of Advanced MR Imaging in Gynecological Tumors and Benign Uterine Fibroids

Not Applicable

Terminated

Conditions: Gynecologic Tumor

Interventions: Device: Magnetic Resonance Fingerprinting (MRF)
Device: Q-space Trajectory Imaging (QTI)
Device: Magnetic Resonance Imaging Machine (MRI)

First Posted Date: 2019-06-20

Last Posted Date: 2020-12-02

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 1

Registration Number: NCT03993210

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts

Phase 1

Recruiting

Conditions: Leukemia

Interventions: Drug: Talazoparib
Drug: Decitabine

First Posted Date: 2019-06-04

Last Posted Date: 2024-07-03

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 12

Registration Number: NCT03974217

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

A Pilot Study of Quantitative Tumor Oxygen Measurements in Cervical Cancer

Active, not recruiting

Conditions: Cervical Cancer
Gynecologic Cancer

First Posted Date: 2019-05-31

Last Posted Date: 2024-10-31

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 10

Registration Number: NCT03970083

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy